251 related articles for article (PubMed ID: 22623769)
21. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
Siddiqi UZ; Vaidya AS; Li X; Marcon E; Tsao SW; Greenblatt J; Frappier L
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341047
[TBL] [Abstract][Full Text] [Related]
22. Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter.
Liu P; Liu S; Speck SH
J Virol; 1998 Oct; 72(10):8230-9. PubMed ID: 9733866
[TBL] [Abstract][Full Text] [Related]
23. The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites.
Kalla M; Göbel C; Hammerschmidt W
J Virol; 2012 Jan; 86(1):447-58. PubMed ID: 22031942
[TBL] [Abstract][Full Text] [Related]
24. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus.
Kraus RJ; Perrigoue JG; Mertz JE
J Virol; 2003 Jan; 77(1):199-207. PubMed ID: 12477825
[TBL] [Abstract][Full Text] [Related]
25. Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells.
Imai K; Kamio N; Cueno ME; Saito Y; Inoue H; Saito I; Ochiai K
FEBS J; 2014 May; 281(9):2148-58. PubMed ID: 24588869
[TBL] [Abstract][Full Text] [Related]
26. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.
Wille CK; Nawandar DM; Panfil AR; Ko MM; Hagemeier SR; Kenney SC
J Virol; 2013 Jan; 87(2):935-50. PubMed ID: 23135711
[TBL] [Abstract][Full Text] [Related]
27. BZLF1 transcript variants in Epstein-Barr virus-positive epithelial cell lines.
Needham J; Adamson AL
Virus Genes; 2019 Dec; 55(6):779-785. PubMed ID: 31552622
[TBL] [Abstract][Full Text] [Related]
28. CpG-methylation regulates a class of Epstein-Barr virus promoters.
Bergbauer M; Kalla M; Schmeinck A; Göbel C; Rothbauer U; Eck S; Benet-Pagès A; Strom TM; Hammerschmidt W
PLoS Pathog; 2010 Sep; 6(9):e1001114. PubMed ID: 20886097
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
30. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
Adamson AL; Kenney SC
Virology; 1998 Nov; 251(1):187-97. PubMed ID: 9813214
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.
Le Roux F; Sergeant A; Corbo L
J Gen Virol; 1996 Mar; 77 ( Pt 3)():501-9. PubMed ID: 8601788
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.
Almohammed R; Osborn K; Ramasubramanyan S; Perez-Fernandez IBN; Godfrey A; Mancini EJ; Sinclair AJ
J Gen Virol; 2018 Jun; 99(6):805-817. PubMed ID: 29580369
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency.
Homa NJ; Salinas R; Forte E; Robinson TJ; Garcia-Blanco MA; Luftig MA
J Virol; 2013 Nov; 87(22):12291-301. PubMed ID: 24027308
[TBL] [Abstract][Full Text] [Related]
34. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
[TBL] [Abstract][Full Text] [Related]
35. Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.
Murata T; Narita Y; Sugimoto A; Kawashima D; Kanda T; Tsurumi T
J Virol; 2013 Sep; 87(18):10148-62. PubMed ID: 23843637
[TBL] [Abstract][Full Text] [Related]
36. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
37. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
38. To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis.
Price AM; Luftig MA
PLoS Pathog; 2015 Mar; 11(3):e1004656. PubMed ID: 25790223
[No Abstract] [Full Text] [Related]
39. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.
Chang LK; Liu ST
Nucleic Acids Res; 2000 Oct; 28(20):3918-25. PubMed ID: 11024171
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein.
Nakayama S; Murata T; Murayama K; Yasui Y; Sato Y; Kudoh A; Iwahori S; Isomura H; Kanda T; Tsurumi T
J Biol Chem; 2009 Aug; 284(32):21557-68. PubMed ID: 19491105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
